Jump to the top of the page

Investment Banking

The Quarterly Rx: Q3 2022 U.S. Biopharma Recap

While biopharma markets stabilized in Q3 2022—providing issuers with the most constructive financing environment we have seen year-to-date—macroeconomic issues remain the key headline risk for the near term. Key biopharma indices bounced off multiyear lows, driven by encouraging signs of M&A, meaningful positive clinical news, and broad sector short covering. William Blair's Biopharma team shares perspectives in “The Quarterly Rx: Q3 2022 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

Subscribe to News Alerts

More News and Insights

  • Graham Corporation: Initiation of Research Coverage

    William Blair initiated research coverage of Graham Corporation (GHM $72.10), a leading design manufacturer of mission-critical fluid, power, heat transfer, vacuum, and advanced mixing technologies.

    Read more

  • Todd McClone, Casey Preyss, and Vivian Lin Thurston Recognized Among Best Fund Managers 2026

    Todd McClone, CFA, partner, portfolio manager; Casey Preyss, CFA, partner, portfolio manager; and Vivian Lin Thurston, CFA, partner, portfolio manager, have been recognized among Handelsblatt Research Institute’s Best Fund Managers 2026 in the Emerging Markets Equity category.

    Read more

  • Deoleo Has Agreed to be Acquired by Acesur and Dcoop

    William Blair acted as the exclusive financial advisor to Deoleo Holding, S.L., a portfolio company of CVC Capital Partners and Alchemy Partners, in connection with its pending sale to a consortium comprising Acesur and Dcoop.

    Read more
See more insights

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures